U
HQL

UBS’s abrdn Life Sciences Investors HQL Stock Holding History

UBS’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1.16M Buy
52,326
+16,224
+45% +$352K ﹤0.01% 3448
2014
Q2 		$750K Buy
36,102
+7,061
+24% +$148K ﹤0.01% 3827
2014
Q1 		$632K Buy
29,041
+9,970
+52% +$222K ﹤0.01% 3988
2013
Q4 		$389K Buy
19,071
+8,783
+85% +$170K ﹤0.01% 4585
2013
Q3 		$198K Buy
10,288
+2,078
+25% +$39.8K ﹤0.01% 5192
2013
Q2 		$147K Buy
+8,210
New +$148K ﹤0.01% 5430

Other funds holding HQL

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

UBS's HQL Position: Q3 2014 in Review

UBS increased its abrdn Life Sciences Investors (HQL) stake by 45% in Q3 2014, buying an estimated $352K and bringing the position to 52,326 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3448.

UBS first reported a position in HQL in Q2 2013 and has held it in 6 quarters since. 49 funds tracked by Wall St. Rank hold HQL as of Q3 2014.

  • UBS held 52,326 shares of abrdn Life Sciences Investors worth $1.16M as of Q3 2014.
  • UBS bought 16,224 abrdn Life Sciences Investors shares in Q3 2014, an estimated $352K.
  • abrdn Life Sciences Investors made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3448 holding.
  • UBS first reported a position in abrdn Life Sciences Investors in Q2 2013 and has held it in 6 quarters since.
  • 49 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.